All Cancer articles – Page 4
-
ArticleBuilding better biologics and a stronger future for women in STEM
Great biologics don’t happen by chance, and neither do great STEM careers. Dr Lidia Serina shares the lessons behind both.
-
NewsHydrogel tech enables global shipping of organoid models
A partnership between Atelerix and Cherry Biotech is enabling the shipping of complex biological models worldwide, using hydrogel preservation technology to eliminate cold-chain logistics.
-
NewsCBD and THC show anti-cancer effects against ovarian tumours
New research suggests cannabis compounds CBD and THC could offer a new approach to treating ovarian cancer.
-
NewsFertility gene PRDM9 linked to relapse in glioblastoma
A study by University of Sydney scientists has discovered why patients with glioblastoma often relapse, identifying a hidden population of cancer cells that hijack a fertility gene to survive chemotherapy.
-
NewsInhibiting DDR1 pathway helps breach pancreatic cancer’s drug barrier
Scientists in Japan have identified a way to weaken the dense fibrotic barrier that prevents drugs from penetrating pancreatic tumours – a promising new strategy that could improve treatment for pancreatic cancer.
-
NewsNew Spheromatrix platform speeds up cancer drug research
Researchers at NYU Abu Dhabi have developed a cheap, paper-based platform that allows tumour models to be grown, frozen and stored for future cancer drug testing – called Spheromatrix.
-
ArticleProtein folding interference: a new path to hard-to-drug targets
Protein folding interference offers access to targets long considered unreachable by traditional drug discovery. By acting on transient folding intermediates, this approach presents a new opportunity to eliminate disease-driving proteins.
-
NewsLive-cell liquid biopsy study aims to transform cancer treatment
Vortex Liquid Biopsy Solutions has launched a new clinical study with The Doctors Laboratory to assess how its live-cell liquid biopsy technology could change cancer monitoring and treatment.
-
NewsBlocking the P2X4 receptor: a potential pathway to new therapies
Researchers have discovered how to inhibit the P2X4 receptor, a key protein linked to chronic pain, inflammation and certain cancers.
-
ArticleLogic-gated DARPins show targeted T-cell activation in tumours
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
-
NewsNew organ-on-a-chip models ageing immune response for cancer vaccines
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
-
NewsMYC inhibitor Omomyc boosts PARP drug response in breast cancer
A preclinical study led by VHIO reveals that the MYC inhibitor Omomyc enhances the effectiveness of PARP inhibitors, offering a potential new treatment strategy for patients with drug-resistant triple-negative breast cancer.
-
ArticleRNA that knows where to go: the rise of targeted delivery
What if RNA medicines could be guided directly to tumours, sparing healthy tissue and reducing side effects? Advances in targeted delivery are bringing that vision closer to reality.
-
NewsFibulin-5 linked to early detection of liver fibrosis
Researchers in Japan have identified a promising blood-based marker that could enable faster, simpler and more accurate detection of liver fibrosis.
-
NewsEstrone hormone linked to deadly breast cancer in obese women
A new analysis has identified the hormone estrone as a major driver of aggressive breast cancer in post-menopausal women with obesity, meaning that weight-loss drugs could help improve treatment outcomes.
-
ArticleThe partnership changing the pace of radiopharmaceutical development
A new collaboration between Crown Bioscience and Medicines Discovery Catapult is bringing advanced tumour models together with world-class imaging and radiochemistry to accelerate the development of next-generation radiopharmaceuticals.
-
NewsAI powers discovery of new CBLB inhibitor ISM3830
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
-
NewsRomidepsin drug combo proves effective against resistant childhood cancer
Australian researchers have identified a promising drug combination that can bypass treatment resistance in relapsed neuroblastoma, offering hope in the fight against one of the deadliest childhood cancers.
-
NewsNew CAR-NKT treatment destroys metastatic pancreatic tumours
A novel CAR-NKT immunotherapy developed at UCLA has shown striking success in preclinical models of metastatic pancreatic cancer, which could hopefully lead to more accessible treatments.
-
ArticleRedesigning paclitaxel: expanding the therapeutic window through oral delivery
The potent chemotherapy drug paclitaxel is widely employed for various cancers despite toxicity and efficacy challenges. Maite Agüeros reveals how novel nanoparticle technology has enabled oral delivery of the drug – showing promising signs of improved tolerability and treatment success.